FILTERED RESULTS
FILTERS
Ads Top
•
·
·
FILTERED RESULTS
Elon Musk Responds To Terminally Ill Teen's Final Questions About Tesla, Anime And SpaceX Mascot Idea
IRAN FORMIN SPOX: OUR DEFENSE CAPABILITIES ARE ABSOLUTELY NOT UP FOR NEGOTIATION...
Apple Fails to Provide Data in India's Antitrust Investigation
Ceasefire at risk after US seizes Iranian ship, Iran shuns peace talks
Major 7.5-magnitude quake hits off Japan, triggers tsunami warnings
FLASH SALE - Lock an InvestingPro subscription for THE LOWEST PRICE OF 2026 NOW
BofA sees Turkey central bank holding rates or hiking to 40%
Exclusive-BOJ is likely to hold off raising rates in April, sources say
Amazon is behind on jobs promised for funding to build Virginia headquarters
High fuel costs threaten GOP in race that could determine House control
Doha could see revival of IPOs, listings in energy sector, post war: KPMG in Qatar
Qatar-Philippines committee meeting set as bilateral trade ties deepen
US/Iran Tensions Rise Ahead of Ceasefire Deadline, Knocking US Stocks - 20 April 2026
IRAN'S BAGHAEI: REMOVING NUCLEAR STOCKPILE FROM IRAN NEVER WAS AN OPTION IN NEGOTIATIONS, TEHRAN'S...
Walmart Targets Amazon's Biggest Edge With Aggressive Delivery Overhaul
Germany’s Wealth Fund Is Dropping Restrictions on Weapons
Gold Tumbles Nearly 2% as Strait of Hormuz Crisis Reignites Market Volatility
The $400 Million Machine That Spawned the World’s Most Coveted Lego Set
Car Owners Are Revolting Over Tesla’s Self-Driving Promises
Twenty7tec Appoints Nick Wakeham as Head of Data Sales
Bank of Japan Expected to Maintain Current Monetary Policy in April
DraftKings Reports Q4 Earnings Amid Industry Comparisons
IRAN FOREIGN MINISTRY SPOKESMAN: THE WITHDRAWAL OF NUCLEAR RESERVES WAS NEVER A NEGOTIATING...
Archer Aviation (ACHR) Stock Surges 24% From Recent Bottom as Investor Confidence Returns
EQT flags growing exit challenges in PE clean energy investments
Groww Profit Tops Estimates; Shares Drop After Post-IPO Rally
Australian pension funds step up European private markets push on UK–France tour
Point72, BlackRock-Backed Contest Seeks Japan Finance Talent
IRAN Foreign Ministry Spokesman: The withdrawal of nuclear reserves was never a negotiating...
American Express (AXP) Stock: Analyst Urges Patience Ahead of Q1 Earnings
Asia private credit sector considers structural tweaks as investor scrutiny intensifies
Economic Data Releases and Fed Nomination Hearings Scheduled for April 20-24
Marvell Technology Shares Rise Amid Google AI Chip Partnership Talks
BlackRock Canada Announces April Cash Distributions for iShares ETFs
Iran Foreign Ministry Criticizes Trump's Statements
Partners Group closes $9bn-plus secondaries programme amid strong global demand
AST SpaceMobile (ASTS) Plunges 14% After Blue Origin Orbital Insertion Mishap
San Diego Padres set for record $3.9bn sale to Clearlake co-founder
AirAsia turns to private credit with $230m Deutsche-led revenue bond
A CEO tries to address affordability with tiny home neighborhoods
JAPAN EARTHQUAKE DEPTH 10KM – NHK...
Iran Wavers on Peace Talks as Tensions Rise After US Seizes Ship
Amazon (AMZN) Shares Surge 4% on $11.6B Globalstar Acquisition as Morgan Stanley Eyes $300
Trump Administration to Begin Refunding $166 Billion in Tariffs
Why Gas Prices Go Up Fast and Take So Long to Fall
A Squabble in D.C. Yields Chaos in El Paso
Peter Schiff Alleges Market Manipulation As $760 Million Bet Draws Scrutiny—Iran Parliamentary Speaker Calls Oil Futures, Treasuries 'House Of Cards'
EUR/USD Signal: Under Pressure Amid Heightened Geopolitical Risks - 20 April 2026
EARTHQUAKE REPORTED IN JAPAN, OFF SANRIKU; 7.4 INITIAL ESTIMATE MAGNITUDE – NHK...
Regeneron Expands Dupixent Indications and Partners with Telix Pharmaceuticals
Regeneron Pharmaceuticals, in collaboration with Sanofi, has received approval from the European Commission for the use of Dupixent in treating moderate to severe chronic spontaneous urticaria in children aged 2 to 11. This new indication broadens Dupixent's existing label in Europe and is backed by clinical data highlighting the significant unmet medical needs in this pediatric population.
In addition to the Dupixent approval, Regeneron has announced a partnership with Telix Pharmaceuticals. The two companies will work together to develop and commercialize next-generation radiopharmaceutical therapies aimed at treating solid tumors. This collaboration marks Regeneron's entry into the radiopharmaceuticals sector, expanding its portfolio in innovative treatment options.
© 2026 KLEA News. All Rights Reserved. This article is provided for informational purposes only. It is not offered or intended to be used as legal, tax, investment, financial, or other advice.
Source: KLEA News